Doan T M Ngo1, Melissa G Farb1, Ryosuke Kikuchi1, Shakun Karki1, Stephanie Tiwari1, Sherman J Bigornia1, David O Bates1, Michael P LaValley1, Naomi M Hamburg1, Joseph A Vita1, Donald T Hess1, Kenneth Walsh1, Noyan Gokce2. 1. From the Evans Department of Medicine and Whitaker Cardiovascular Institute (D.T.M.N., M.G.F., R.K., S.K., S.T., S.J.B., N.M.H., J.A.V., K.W., N.G.) and Department of General Surgery (D.T.H.), Boston University School of Medicine, Boston, MA; Microvascular Research Laboratories, School of Physiology and Pharmacology, Bristol Heart Institute, School of Veterinary Science, University of Bristol, Bristol, UK (D.O.B.); and Department of Biostatistics, Boston University School of Public Health, Boston, MA (M.P.L.). 2. From the Evans Department of Medicine and Whitaker Cardiovascular Institute (D.T.M.N., M.G.F., R.K., S.K., S.T., S.J.B., N.M.H., J.A.V., K.W., N.G.) and Department of General Surgery (D.T.H.), Boston University School of Medicine, Boston, MA; Microvascular Research Laboratories, School of Physiology and Pharmacology, Bristol Heart Institute, School of Veterinary Science, University of Bristol, Bristol, UK (D.O.B.); and Department of Biostatistics, Boston University School of Public Health, Boston, MA (M.P.L.). Noyan.Gokce@bmc.org.
Abstract
BACKGROUND: Experimental studies suggest that visceral adiposity and adipose tissue dysfunction play a central role in obesity-related cardiometabolic complications. Impaired angiogenesis in fat has been implicated in the development of adipose tissue hypoxia, capillary rarefaction, inflammation, and metabolic dysregulation, but pathophysiological mechanisms remain unknown. In this study, we examined the role of a novel antiangiogenic isoform of vascular endothelial growth factor-A (VEGF-A), VEGF-A165b, in human obesity. METHODS AND RESULTS: We biopsied paired subcutaneous and visceral adipose tissue in 40 obese subjects (body mass index, 45±8 kg/m(2); age, 45±11 years) during bariatric surgery and characterized depot-specific adipose tissue angiogenic capacity using an established ex vivo assay. Visceral adipose tissue exhibited significantly blunted angiogenic growth compared with subcutaneous fat (P<0.001) that was associated with marked tissue upregulation of VEGF-A165b (P=0.004). The extent of VEGF-A165b expression correlated negatively with angiogenic growth (r=-0.6, P=0.006). Although recombinant VEGF-A165b significantly impaired angiogenesis, targeted inhibition of VEGF-A165b with neutralizing antibody stimulated fat pad neovascularization and restored VEGF receptor activation. Blood levels of VEGF-A165b were significantly higher in obese subjects compared with lean control subjects (P=0.02), and surgical weight loss induced a marked decline in serumVEGF-A165b (P=0.003). CONCLUSIONS: We demonstrate that impaired adipose tissue angiogenesis is associated with overexpression of a novel antiangiogenic factor, VEGF-A165b, that may play a pathogenic role in human adiposopathy. Moreover, systemic upregulation of VEGF-A165b in circulating blood may have wider-ranging implications beyond the adipose milieu. VEGF-A165b may represent a novel area of investigation to gain further understanding of mechanisms that modulate the cardiometabolic consequences of obesity.
BACKGROUND: Experimental studies suggest that visceral adiposity and adipose tissue dysfunction play a central role in obesity-related cardiometabolic complications. Impaired angiogenesis in fat has been implicated in the development of adipose tissue hypoxia, capillary rarefaction, inflammation, and metabolic dysregulation, but pathophysiological mechanisms remain unknown. In this study, we examined the role of a novel antiangiogenic isoform of vascular endothelial growth factor-A (VEGF-A), VEGF-A165b, in humanobesity. METHODS AND RESULTS: We biopsied paired subcutaneous and visceral adipose tissue in 40 obese subjects (body mass index, 45±8 kg/m(2); age, 45±11 years) during bariatric surgery and characterized depot-specific adipose tissue angiogenic capacity using an established ex vivo assay. Visceral adipose tissue exhibited significantly blunted angiogenic growth compared with subcutaneous fat (P<0.001) that was associated with marked tissue upregulation of VEGF-A165b (P=0.004). The extent of VEGF-A165b expression correlated negatively with angiogenic growth (r=-0.6, P=0.006). Although recombinant VEGF-A165b significantly impaired angiogenesis, targeted inhibition of VEGF-A165b with neutralizing antibody stimulated fat pad neovascularization and restored VEGF receptor activation. Blood levels of VEGF-A165b were significantly higher in obese subjects compared with lean control subjects (P=0.02), and surgical weight loss induced a marked decline in serumVEGF-A165b (P=0.003). CONCLUSIONS: We demonstrate that impaired adipose tissue angiogenesis is associated with overexpression of a novel antiangiogenic factor, VEGF-A165b, that may play a pathogenic role in human adiposopathy. Moreover, systemic upregulation of VEGF-A165b in circulating blood may have wider-ranging implications beyond the adipose milieu. VEGF-A165b may represent a novel area of investigation to gain further understanding of mechanisms that modulate the cardiometabolic consequences of obesity.
Authors: Melissa G Farb; Sherman Bigornia; Melanie Mott; Kahraman Tanriverdi; Kristine M Morin; Jane E Freedman; Lija Joseph; Donald T Hess; Caroline M Apovian; Joseph A Vita; Noyan Gokce Journal: J Am Coll Cardiol Date: 2011-07-12 Impact factor: 24.094
Authors: Olga Gealekman; Nina Guseva; Celia Hartigan; Sarah Apotheker; Matthew Gorgoglione; Kunal Gurav; Khan-Van Tran; Juerg Straubhaar; Sarah Nicoloro; Michael P Czech; Michael Thompson; Richard A Perugini; Silvia Corvera Journal: Circulation Date: 2011-01-03 Impact factor: 29.690
Authors: Jeanette Woolard; Wen-Ying Wang; Heather S Bevan; Yan Qiu; Lucia Morbidelli; Rowan O Pritchard-Jones; Tai-Gen Cui; Marto Sugiono; Elizabeth Waine; Rachel Perrin; Rebecca Foster; Jonathon Digby-Bell; Jacqueline D Shields; Cheryl E Whittles; Rosey E Mushens; David A Gillatt; Marina Ziche; Steven J Harper; David O Bates Journal: Cancer Res Date: 2004-11-01 Impact factor: 12.701
Authors: O Gealekman; N Guseva; K Gurav; A Gusev; C Hartigan; M Thompson; S Malkani; S Corvera Journal: Diabetologia Date: 2012-07-31 Impact factor: 10.122
Authors: Hoon-Ki Sung; Kyung-Oh Doh; Joe Eun Son; Jin Gyoon Park; Yunui Bae; Soojeong Choi; Seana Mary Lunney Nelson; Rebecca Cowling; Kristina Nagy; Iacovos P Michael; Gou Young Koh; S Lee Adamson; Tony Pawson; Andras Nagy Journal: Cell Metab Date: 2013-01-08 Impact factor: 27.287
Authors: Bee K Tan; Raghu Adya; Jing Chen; Syed Farhatullah; Dennis Heutling; Dan Mitchell; Hendrik Lehnert; Harpal S Randeva Journal: Cardiovasc Res Date: 2009-05-04 Impact factor: 10.787
Authors: Shakun Karki; Melissa G Farb; Doan T M Ngo; Samantha Myers; Vishwajeet Puri; Naomi M Hamburg; Brian Carmine; Donald T Hess; Noyan Gokce Journal: Arterioscler Thromb Vasc Biol Date: 2015-04-23 Impact factor: 8.311
Authors: Doan T M Ngo; Aaron L Sverdlov; Shakun Karki; Donia Macartney-Coxson; Richard S Stubbs; Melissa G Farb; Brian Carmine; Donald T Hess; Wilson S Colucci; Noyan Gokce Journal: Am J Physiol Endocrinol Metab Date: 2018-12-21 Impact factor: 4.310